To the Editor:
Kawashiri, et al recently reported that biologic disease-modifying antirheumatic drugs (DMARD; i.e., infliximab, etanercept, and tocilizumab) may have therapeutic efficacy by inhibiting CCL20 production in rheumatoid synovium1. Indeed, serum CCL20 concentration in patients with rheumatoid arthritis (RA) was clearly decreased by treatment with biologic DMARD. As well, DMARD also can inhibit the production …
Address correspondence to Prof. D-Q. Ye; E-mail: ydq{at}ahmu.edu.cn